|
Study Name | Study Type | Sample Size, Mean Age in Years (Range), and Years since Menopause | Type of Therapy | Dose | Treatment Duration | Results for BMD, BMC, or Fracture Risk |
|
ULTRA Trial [39] | RCT | 417, 67 (60–80), 5 years | E2 patch or placebo patch* | E2: 0.014 mg/day | 2 years | 2.1% greater LV BMD versus placebo. |
|
HOPE Trial [40] | RCT | 822, 51.6 (40–65), 1 to 4 years | CEE, CEE + MPA, or placebo* | CEE: 0.625, 0.45, or 0.3 mg/d MPA: 2.5 or 1.5 mg/d | 2 years | 1.33–3.46% increase in LV BMD; Approximately 1.5–3% increase in hip BMD; 1.03–1.74% increase in total BMC, with these doses. |
|
Gambacciani et al, 2008 [41] | Open Trial | Sample size not provided, 57 (range not provided), 1 year | E2 + NA (oral) or no treatment* | 1 mg E2 + 0.5 mg NA for 28 d or 0.5 mg E2 + 0.25 mg NA per day | 2 years | 2–5% increase in LV BMD; 1.8–2.8% increase in femur neck BMD, with these doses. |
|
Garcia-Pérez et al, 2006 [42] | Transversal Study | 136, 53 for 0.05 mg/d and placebo groups to 56 for 0.025 mg/d group (range not provided), 1 year | E2 patch + micronized progesterone, or placebo* | E2: 0.05 or 0.025 mg/d progesterone: 100 mg/d | 18 months | 0.73–0.92% increase in femur neck BMD; .35–0.87% change in LV BMD, with these doses. |
|
Gambacciani et al, 2001 [43] | Open Trial | 38,54 (45–56), 1 year | CEE + MPA* | CEE: 0.3 mg/d MPA: 2.5 mg/d | 2 years | 2.7% increase in LV BMD. |
|